The current epidemic of non-alcoholic fatty liver disease (NAFLD) is reshaping the field of
hepatology all around the world. The widespread diffusion of metabolic risk factors such as …

The correct identification of patients at increased risk of non-alcoholic steatohepatitis
(NASH) and advanced fibrosis is a critical step in the assessment of non-alcoholic fatty liver …

Since the publication of the guidelines for the assessment and management of non alcoholic
fatty liver disease (NAFLD) by the Asia–Pacific Working Party on NAFLD in 2007, 1 our …

Background Non‐alcoholic fatty liver disease (NAFLD) affects 20%‐40% of the general
population in developed countries and is an increasingly important cause of hepatocellular …

Background & Aims Perpetuate liver inflammation is crucial in the pathogenesis of non-
alcoholic steatohepatitis (NASH). Expression of CXCL10, a pro-inflammatory cytokine …

Liver biopsy still remains the gold standard for diagnosing nonalcoholic steatohepatitis
(NASH), but with limitations. There is an urgent need to develop noninvasive tests that …

Introduction Association between elevated cytokeratin 18 (CK-18) levels and hepatocyte
death has made circulating CK-18 a candidate biomarker to differentiate non-alcoholic fatty …

The development of non invasive biomarkers of disease has become a major focus of
interest in nonalcoholic fatty liver disease (NAFLD). The large prevalence of the disease and …

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition
characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that …

Keratins, formerly known as cytokeratins, are the major epithelial‐specific subgroup of
intermediate filament proteins. Adult hepatocytes express keratin polypeptides 8 and 18 …